News | April 11, 2025
Orchid Pharma to settle disputes with DBS Bank
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Subscribe To Our Newsletter & Stay Updated
